However , there was a dose-response association for non-serious adverse events during the treatment phase ( days 1-6 ) ; one patient in the placebo group , three patients in the 0.33 MIU group , five patients in the 1 MIU group , and six patients in the 3 MIU group had non-serious adverse events .